Literature DB >> 22699072

[Pathological changes of monocrotaline-induced pulmonary hypertension in miniature pigs].

Jin Zhao1, Rong Liu, Hongtao Li, Xinfeng Zhang, Baohua Liu, Qinghong Wu, Yuanxin Qian, Weiwang Gu.   

Abstract

OBJECTIVE: To observe the pathological changes in the myocardial and pulmonary tissues in miniature pigs with chronic pulmonary hypertension induced by monocrotaline (MCT).
METHODS: Twelve male miniature pigs (weigh 15.0-18.0 kg, aged 4.0-4.5 months) were examined for baseline mean pulmonary artery pressure (mPAP), followed by intraperitoneal injection of 10.0 mg/kg MCT in 10 randomly selected pigs. The mean pulmonary artery pressure at 4 and 8 weeks were determined, and the pathological changes in the myocardial and pulmonary tissues were observed.
RESULTS: The baseline mPAP of normal miniature pigs was 15.19∓0.70 mmHg. At 4 and 8 weeks after MCT injection, the sPAP and dPAP were 19.69∓2.47 mmHg and 25.62∓4.88 mmHg, respectively, and the mPAP increased significantly compared with that of the normal control group (P<0.01). Obvious pathological changes such as pulmonary hypertension and right ventricular hypertrophy were found in the pigs 4 weeks after MCT injection, and at 8 weeks, significant pathological changes occurred including right ventricular fibrosis and thickening of the tunica media of the pulmonary artery.
CONCLUSION: MCT can cause pulmonary hypertension in miniature pigs 8 weeks after drug administration, shown as increased pulmonary artery pressure and pulmonary vascular remodeling.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22699072

Source DB:  PubMed          Journal:  Nan Fang Yi Ke Da Xue Xue Bao        ISSN: 1673-4254


  1 in total

1.  Single intraperitoneal injection of monocrotaline as a novel large animal model of chronic pulmonary hypertension in Tibet minipigs.

Authors:  Guang-qiao Zeng; Rong Liu; Hai-xing Liao; Xin-feng Zhang; Yuan-xin Qian; Bao-hua Liu; Qing-hong Wu; Jin Zhao; Wei-wang Gu; Hong-tao Li
Journal:  PLoS One       Date:  2013-11-11       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.